Are 19del and L858R really different disease entities?
Future Oncol
; : 1-6, 2024 Sep 16.
Article
em En
| MEDLINE
| ID: mdl-39279671
ABSTRACT
Clinicians have recognized the similarities and differences between the two subtypes of common epidermal growth factor receptor (EGFR) mutations, but actual treatment strategies have not yet changed. The L858R mutation can be understood by considering the pharmacological conformational plasticity of the receptor protein and the presence of other co-occurring mutations, whether subtypes of EGFR or non-EGFR mutations and differences in downstream signaling pathways. As long as we know that molecular differences lead to biological differences, it is a challenge for all of us that our treatment strategies must change.
[Box see text].
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2024
Tipo de documento:
Article